Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308398762> ?p ?o ?g. }
- W4308398762 abstract "<h3>Background</h3> The anti–PD-1 monoclonal antibody pembrolizumab has a tumor-agnostic approval by the US FDA for previously treated advanced tumors characterized as microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR). Although several studies have reported on the global prevalence of MSI-H/dMMR, data on the prevalence of dMMR across advanced solid tumor types in Chinese patients are limited. Here, we report real-world data on dMMR across 5 tumor types in Chinese patients. <h3>Methods</h3> Adult patients with treatment-naive or previously treated advanced (stage III/IV) biliary tract, cervical, endometrial, gastric, or ovarian cancer from 5 study centers in China were included in this analysis. MMR testing was performed on archival formalin-fixed, paraffin-embedded tissue samples using the Ventana MMR RxDx panel. The primary objective of this study was to determine the prevalence of dMMR. Secondary objectives were to assess clinicopathologic characteristics and treatment patterns. <h3>Results</h3> Of 748 patients who had tissue samples evaluable for MMR status, 314 (42.0%) had gastrointestinal (GI) tumors and 434 (58.0%) had gynecologic (GYN) tumors. The prevalence of dMMR was 9.4% (70/748) overall, 4.1% (13/314) in GI tumors (4.3% [8/186] biliary tract, 3.9% [5/128] gastric) and 13.1% (57/434) in GYN tumors (2.7% [6/221] cervical, 29.9% [49/164] endometrial, 4.1% [2/49] ovarian). In the dMMR population (n = 70), most patients were aged 18–65 years (88.6%), had stage III disease at diagnosis (78.6%), and had undergone surgery (91.4%). At the protein level, the frequency of a co-occurring loss of MLH1 and PMS2 in patients with dMMR tumors was 68.6% (table 1), which is consistent with global reports in colorectal cancer. Evaluation of the treatment history of dMMR versus the proficient mismatch repair populations showed that a higher proportion of patients with dMMR tumors received radiation (40.0% vs 23.0%), chemotherapy (70.0% vs 48.5%), and/or treatment with immune checkpoint inhibitors (11.4% vs 4.6%) at some point since their initial diagnosis. <h3>Conclusions</h3> Prevalence of dMMR and co-occurring loss of MLH1 and PMS2 at the protein level across the 5 different tumor types in Chinese patients are consistent with reports in the literature. <h3>Acknowledgements</h3> Medical writing and/or editorial assistance was provided by Obinna T. Ezeokoli, PhD, and Holly C. Cappelli, PhD, CMPP of ApotheCom (Yardley, PA, USA). This assistance was funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. <h3>Consent</h3> Written informed consent was provided by all patients before use/analysis of tumor specimen." @default.
- W4308398762 created "2022-11-11" @default.
- W4308398762 creator A5003642180 @default.
- W4308398762 creator A5025682608 @default.
- W4308398762 creator A5045314919 @default.
- W4308398762 creator A5047090672 @default.
- W4308398762 creator A5048874956 @default.
- W4308398762 creator A5050505549 @default.
- W4308398762 creator A5052073934 @default.
- W4308398762 creator A5056053058 @default.
- W4308398762 creator A5057136360 @default.
- W4308398762 creator A5062852782 @default.
- W4308398762 creator A5071458554 @default.
- W4308398762 creator A5072969391 @default.
- W4308398762 creator A5080003280 @default.
- W4308398762 creator A5086085006 @default.
- W4308398762 date "2022-11-01" @default.
- W4308398762 modified "2023-10-17" @default.
- W4308398762 title "32 Real-world prevalence of deficient mismatch repair across 5 solid tumor types in China" @default.
- W4308398762 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0032" @default.
- W4308398762 hasPublicationYear "2022" @default.
- W4308398762 type Work @default.
- W4308398762 citedByCount "0" @default.
- W4308398762 crossrefType "proceedings-article" @default.
- W4308398762 hasAuthorship W4308398762A5003642180 @default.
- W4308398762 hasAuthorship W4308398762A5025682608 @default.
- W4308398762 hasAuthorship W4308398762A5045314919 @default.
- W4308398762 hasAuthorship W4308398762A5047090672 @default.
- W4308398762 hasAuthorship W4308398762A5048874956 @default.
- W4308398762 hasAuthorship W4308398762A5050505549 @default.
- W4308398762 hasAuthorship W4308398762A5052073934 @default.
- W4308398762 hasAuthorship W4308398762A5056053058 @default.
- W4308398762 hasAuthorship W4308398762A5057136360 @default.
- W4308398762 hasAuthorship W4308398762A5062852782 @default.
- W4308398762 hasAuthorship W4308398762A5071458554 @default.
- W4308398762 hasAuthorship W4308398762A5072969391 @default.
- W4308398762 hasAuthorship W4308398762A5080003280 @default.
- W4308398762 hasAuthorship W4308398762A5086085006 @default.
- W4308398762 hasBestOaLocation W43083987621 @default.
- W4308398762 hasConcept C104317684 @default.
- W4308398762 hasConcept C121608353 @default.
- W4308398762 hasConcept C126322002 @default.
- W4308398762 hasConcept C143998085 @default.
- W4308398762 hasConcept C146357865 @default.
- W4308398762 hasConcept C151730666 @default.
- W4308398762 hasConcept C180754005 @default.
- W4308398762 hasConcept C185592680 @default.
- W4308398762 hasConcept C2777088508 @default.
- W4308398762 hasConcept C2777701055 @default.
- W4308398762 hasConcept C2778220009 @default.
- W4308398762 hasConcept C2778822529 @default.
- W4308398762 hasConcept C2779134260 @default.
- W4308398762 hasConcept C2779767149 @default.
- W4308398762 hasConcept C2779984678 @default.
- W4308398762 hasConcept C2780057760 @default.
- W4308398762 hasConcept C2780427987 @default.
- W4308398762 hasConcept C2908647359 @default.
- W4308398762 hasConcept C526805850 @default.
- W4308398762 hasConcept C55493867 @default.
- W4308398762 hasConcept C60748783 @default.
- W4308398762 hasConcept C61320498 @default.
- W4308398762 hasConcept C71924100 @default.
- W4308398762 hasConcept C86803240 @default.
- W4308398762 hasConcept C99454951 @default.
- W4308398762 hasConceptScore W4308398762C104317684 @default.
- W4308398762 hasConceptScore W4308398762C121608353 @default.
- W4308398762 hasConceptScore W4308398762C126322002 @default.
- W4308398762 hasConceptScore W4308398762C143998085 @default.
- W4308398762 hasConceptScore W4308398762C146357865 @default.
- W4308398762 hasConceptScore W4308398762C151730666 @default.
- W4308398762 hasConceptScore W4308398762C180754005 @default.
- W4308398762 hasConceptScore W4308398762C185592680 @default.
- W4308398762 hasConceptScore W4308398762C2777088508 @default.
- W4308398762 hasConceptScore W4308398762C2777701055 @default.
- W4308398762 hasConceptScore W4308398762C2778220009 @default.
- W4308398762 hasConceptScore W4308398762C2778822529 @default.
- W4308398762 hasConceptScore W4308398762C2779134260 @default.
- W4308398762 hasConceptScore W4308398762C2779767149 @default.
- W4308398762 hasConceptScore W4308398762C2779984678 @default.
- W4308398762 hasConceptScore W4308398762C2780057760 @default.
- W4308398762 hasConceptScore W4308398762C2780427987 @default.
- W4308398762 hasConceptScore W4308398762C2908647359 @default.
- W4308398762 hasConceptScore W4308398762C526805850 @default.
- W4308398762 hasConceptScore W4308398762C55493867 @default.
- W4308398762 hasConceptScore W4308398762C60748783 @default.
- W4308398762 hasConceptScore W4308398762C61320498 @default.
- W4308398762 hasConceptScore W4308398762C71924100 @default.
- W4308398762 hasConceptScore W4308398762C86803240 @default.
- W4308398762 hasConceptScore W4308398762C99454951 @default.
- W4308398762 hasLocation W43083987621 @default.
- W4308398762 hasOpenAccess W4308398762 @default.
- W4308398762 hasPrimaryLocation W43083987621 @default.
- W4308398762 hasRelatedWork W2127503099 @default.
- W4308398762 hasRelatedWork W2472189030 @default.
- W4308398762 hasRelatedWork W2587709415 @default.
- W4308398762 hasRelatedWork W2991210834 @default.
- W4308398762 hasRelatedWork W3161467143 @default.
- W4308398762 hasRelatedWork W3207036495 @default.
- W4308398762 hasRelatedWork W4200297282 @default.
- W4308398762 hasRelatedWork W4210362744 @default.